A positive FY Trading Update that came in slightly ahead of our, and the market's expectations, with revenue of £13.9m vs. our £13.7m estimate. US Dollar (representing the majority of revenue) performance reflected the true operational growth, up some 17% YoY before the FX impact reduced that to 10% growth in GBP (reported) terms. EBITDA (adjusted for share-based payments) was up 294% to £2.1m, and the DXRX platform has grown to provide 57% of group revenue. The company has also announced a new CFO to replace Philip White, who is moving on to undertake his own projects.
11 Jan 2022
Diaceutics - Quick Take - FY Trading Update
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Diaceutics - Quick Take - FY Trading Update
Diaceutics Plc (DXRX:LON) | 103 0 0.0% | Mkt Cap: 87.2m
- Published:
11 Jan 2022 -
Author:
Oliver Juggins -
Pages:
7
A positive FY Trading Update that came in slightly ahead of our, and the market's expectations, with revenue of £13.9m vs. our £13.7m estimate. US Dollar (representing the majority of revenue) performance reflected the true operational growth, up some 17% YoY before the FX impact reduced that to 10% growth in GBP (reported) terms. EBITDA (adjusted for share-based payments) was up 294% to £2.1m, and the DXRX platform has grown to provide 57% of group revenue. The company has also announced a new CFO to replace Philip White, who is moving on to undertake his own projects.